Literature DB >> 9084416

Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.

C S Breivogel1, D E Selley, S R Childers.   

Abstract

To compare activation of G proteins by opioid receptors, opioid agonist-stimulated guanosine 5'-O-(3-[35S]thiotriphosphate) ([35S]GTP gamma S) binding in the presence of excess GDP was assayed in membranes from NG108-15 (delta) and SK-N-SH (primarily mu) cells. Basal [35S]GTP gamma S binding consisted of a single class of low-affinity sites (KD 400-500 nM). Addition of agonists produced a high-affinity site 100-300-fold higher in affinity than the basal site. The receptor/transducer amplification factor (ratio of activated G protein Bmax to opioid receptor Bmax) was 10-fold higher for SK-N-SH mu receptors than for NG108-15 delta receptors. Chronic delta agonist ([D-Ser2]-Leu-enkephalin-Thr; DSLET) treatment of NG108-15 cells resulted in an 80% loss of DSLET-stimulated [35S]-GTP gamma S binding within 1 h. Morphine treatment of SK-N-SH cells decreased mu agonist ([D-Ala2, N-Me-Phe4,Gly5-ol]-enkephalin; DAMGO)-stimulated [35S]GTP gamma S binding by 45% after 16 h, with no effect after 1 h. Loss of agonist response was due to a decrease in the Bmax of activated G proteins with no change in the KD. These results provide a quantitative description of G protein activation occurring on acute and chronic exposure to opioid agonists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084416     DOI: 10.1046/j.1471-4159.1997.68041462.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

2.  Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1β: evidence for opioid-immune crosstalk.

Authors:  Shekher Mohan; Randall L Davis; Udaya DeSilva; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2010-07-07       Impact factor: 3.478

3.  Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors.

Authors:  M Shapira; Z Vogel; Y Sarne
Journal:  Cell Mol Neurobiol       Date:  2000-06       Impact factor: 5.046

4.  Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain.

Authors:  L J Sim-Selley; D E Selley; L J Vogt; S R Childers; T J Martin
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

5.  Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.

Authors:  D E Selley; C C Cao; Q Liu; S R Childers
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Time-dependent changes in receptor/G-protein coupling in rat brain following chronic monoamine transporter blockade.

Authors:  Kerry A O'Connor; Linda J Porrino; Huw M L Davies; Steven R Childers
Journal:  J Pharmacol Exp Ther       Date:  2005-01-11       Impact factor: 4.030

7.  Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.

Authors:  L J Sim-Selley; K L Scoggins; M P Cassidy; L A Smith; W L Dewey; F L Smith; D E Selley
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 8.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

9.  Ligand-specific regulation of the endogenous mu-opioid receptor by chronic treatment with mu-opioid peptide agonists.

Authors:  Marianna Murányi; Resat Cinar; Orsolya Kékesi; Erika Birkás; Gabriella Fábián; Beáta Bozó; András Zentai; Géza Tóth; Emese Gabriella Kicsi; Mónika Mácsai; Roberta Dochnal; Gyula Szabó; Mária Szücs
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.